Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Amgen Inc. is an independent biotechnology medicines company that discovers, develops, manufactures and markets medicines for grievous illnesses. The Company focuses solely on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology.
Website: amgen.com



Growth: Bad revenue growth rate -70.5%, there is slowdown compared to average historical growth rates 27.0%. The revenue growth dynamics is unstable Site traffic for the last 3 months showed a change of +3.7%

Profitability: LTM EBITDA margin is positive, +59.4%. On average the margin is improving unsteadily. Gross margin is high, +82.5%. In the last quarter the company beat the estimated EPS, +3.4%. The company was ahead of estimated EPS in 100% of quarters (showing a gain of +$0.16 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 2.5%. Free cash flow yield 4.3% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 79.4% higher than minimum and 0.0% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 4.3x by EV / Sales multiple , the company can be 3.8% undervalued

Insiders: For the last 3 months insiders sold company shares on $3.7 mln (-0.002% of cap.)

Key Financials (Download financials)

Ticker: AMGN
Share price, USD:  (+4.5%)384.32
year average price 302.72  


year start price 293.54 2025-02-08

min close price 262.28 2025-05-14

max close price 384.32 2026-02-06

current price 384.32 2026-02-07
Common stocks: 534 425 944

Dividend Yield:  2.5%
FCF Yield LTM: 4.3%
EV / LTM EBITDA: 7.0x
EV / EBITDA annualized: 4.6x
Last revenue growth (y/y):  +33.4%
Last growth of EBITDA (y/y):  > +200.0%
Historical revenue growth:  +27.0%
Historical growth of EBITDA:  +43.2%
EV / Sales: 4.2x
Margin (EBITDA LTM / Revenue): 59.4%
Fundamental value created in LTM:
Market Cap ($m): 205 391
Net Debt ($m): 45 475
EV (Enterprise Value): 250 866
Price to Book: 23.7x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2026-02-04zacks.com

Amgen (AMGN) Stock Hits 52-Week Highs: Buy Signal?

2026-02-04forbes.com

Why Amgen Stock Is Paying Off Big For Long-Term Investors

2026-02-03seekingalpha.com

Amgen Inc. (AMGN) Q4 2025 Earnings Call Transcript

2026-02-03zacks.com

Amgen (AMGN) Q4 Earnings and Revenues Beat Estimates

2026-01-29zacks.com

Amgen (AMGN) is a Top-Ranked Value Stock: Should You Buy?

2026-01-29zacks.com

Countdown to Amgen (AMGN) Q4 Earnings: Wall Street Forecasts for Key Metrics

2026-01-26zacks.com

Amgen (AMGN) Laps the Stock Market: Here's Why

2026-01-26zacks.com

Here's Why Amgen (AMGN) is a Strong Momentum Stock

2026-01-23zacks.com

Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock

2026-01-22seekingalpha.com

Amgen: A Buy In 2026 On Exciting MariTide Obesity - T2D Potential
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q4 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-12-31 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol AMGN AMGN AMGN AMGN AMGN AMGN AMGN AMGN AMGN AMGN AMGN AMGN AMGN AMGN AMGN
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 318 154 318 154 318 154 318 154 318 154 318 154 318 154 318 154 318 154 318 154 318 154 318 154 318 154 318 154 318 154
filingDate 2026-02-03 2025-02-14 2024-02-14 2023-02-09 2022-02-16 2021-02-09
acceptedDate 2026-02-03 16:03:07 2025-11-04 18:59:36 2025-08-05 19:13:42 2025-02-14 16:18:41 2024-10-30 18:43:20 2024-08-06 18:54:26 2024-05-02 19:27:57 2024-02-14 16:23:32 2023-10-31 16:21:57 2023-08-03 19:28:03 2023-04-27 20:38:17 2023-02-09 16:26:31 2022-11-03 19:24:04 2022-02-16 16:39:53 2021-02-08 19:24:56
fiscalYear 2025 2024 2023 2022 2021 2020
period FY Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 36 751M 9 557M 9 167M 33 424M 8 503M 8 333M 7 396M 28 190M 6 903M 6 986M 6 105M 26 323M 6 652M 25 979M 25 424M
costOfRevenue 6 423M 3 082M 3 011M 12 858M 3 310M 3 236M 3 200M 8 415M 1 806M 1 813M 1 720M 6 406M 1 588M 6 454M 6 159M
grossProfit 30 328M 6 475M 6 156M 20 566M 5 193M 5 097M 4 196M 19 775M 5 097M 5 173M 4 385M 19 917M 5 064M 19 525M 19 265M
researchAndDevelopmentExpenses 7 272M 1 900M 1 744M 5 964M 1 450M 1 447M 1 343M 4 784M 1 079M 1 113M 1 058M 4 434M 1 112M 6 324M 4 207M
generalAndAdministrativeExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 7 050M 1 720M 1 691M 7 096M 1 625M 1 785M 1 808M 6 179M 1 353M 1 294M 1 258M 5 414M 1 287M 5 368M 5 730M
otherExpenses 1 115M 329M 77M 248M 71M -11M -105M 879M 685M -318M 148M 503M 5M 194M 189M
operatingExpenses 15 437M 3 949M 3 512M 13 308M 3 146M 3 243M 3 256M 11 842M 3 076M 2 489M 2 464M 10 351M 2 404M 11 886M 10 126M
costAndExpenses 21 860M 7 031M 6 523M 26 166M 6 456M 6 479M 6 456M 20 293M 4 882M 4 302M 4 184M 16 757M 3 992M 18 340M 16 285M
netInterestIncome -2 755M -3 155M -2 875M -1 406M -1 197M -1 262M
interestIncome 0 0 0 0 0 0 0 0 759M 0 0 0 0 0 0
interestExpense 2 755M 685M 708M 3 155M 776M 808M 824M 2 875M 759M 752M 543M 1 406M 368M 1 197M 1 262M
depreciationAndAmortization 5 380M 1 307M 1 341M 5 592M 1 396M 1 400M 1 399M 4 071M 685M -318M 900M 3 417M 937M 3 398M 3 601M
ebitda 17 133M 5 913M 3 617M 13 356M 5 288M 3 322M 2 339M 14 801M 2 706M 2 366M 3 985M 12 169M 3 597M 11 296M 12 996M
ebit 11 753M 7 764M 10 730M 8 752M 7 898M 9 395M
nonOperatingIncomeExcludingInterest 3 138M -506M -2 833M 814M -259M -256M
operatingIncome 14 891M 2 526M 2 644M 7 258M 2 047M 1 854M 940M 7 897M 2 021M 2 684M 3 085M 9 566M 2 660M 7 639M 9 139M
totalOtherIncomeExpensesNet -5 915M 1 395M -1 076M -2 649M 1 054M -1 115M -1 008M -42M 685M -318M 357M -2 220M -268M -938M -1 006M
incomeBeforeTax 8 976M 3 921M 1 568M 4 609M 3 101M 794M -68M 7 855M 1 947M 1 614M 3 442M 7 346M 2 392M 6 701M 8 133M
incomeTaxExpense 1 265M 705M 136M 519M 271M 48M 45M 1 138M 217M 235M 601M 794M 249M 808M 869M
netIncomeFromContinuingOperations 7 711M 4 090M 6 717M 6 552M 5 893M 7 264M
netIncomeFromDiscontinuedOperations 0 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0 0
netIncome 7 711M 3 216M 1 432M 4 090M 2 830M 746M -113M 6 717M 1 730M 1 379M 2 841M 6 552M 2 143M 5 893M 7 264M
netIncomeDeductions 0 0 0 0 0 0
bottomLineNetIncome 7 711M 4 090M 6 717M 6 552M 5 893M 7 264M
eps 14.33 5.98 2.66 7.62 5.27 1.39 -0.21 12.56 3.23 2.58 5.32 12.18 4.01 10.34 12.4
epsDiluted 14.23 7.56 12.49 12.11 10.28 12.31
weightedAverageShsOut 538M 538M 538M 541M 537M 537M 536M 535M 535M 535M 534M 538M 535M 570M 586M
weightedAverageShsOutDil 542M 542M 541M 541M 542M 541M 536M 538M 538M 537M 538M 541M 538M 573M 590M
fillingDate 2025-11-05 2025-08-06 2024-10-31 2024-08-07 2024-05-03 2023-10-31 2023-08-04 2023-04-28 2022-11-04
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
grossProfitRatio 0.678 0.672 0.611 0.612 0.567 0.738 0.74 0.718 0.761
ebitdaratio 0.619 0.395 0.622 0.39 0.316 0.392 0.339 0.653 0.541
operatingIncomeRatio 0.264 0.288 0.241 0.222 0.127 0.293 0.384 0.505 0.4
incomeBeforeTaxRatio 0.41 0.171 0.365 0.095 -0.009 0.282 0.231 0.564 0.36
netIncomeRatio 0.337 0.156 0.333 0.09 -0.015 0.251 0.197 0.465 0.322
epsdiluted 5.93 2.65 5.22 1.38 -0.21 3.22 2.57 5.28 3.98
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2025 q4 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-12-31 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol AMGN AMGN AMGN AMGN AMGN AMGN AMGN AMGN AMGN AMGN AMGN AMGN AMGN AMGN AMGN
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 318 154 318 154 318 154 318 154 318 154 318 154 318 154 318 154 318 154 318 154 318 154 318 154 318 154 318 154 318 154
filingDate 2026-02-03 2025-02-14 2024-02-14 2023-02-09 2022-02-16 2021-02-09
acceptedDate 2026-02-03 16:03:07 2025-11-04 18:59:36 2025-08-05 19:13:42 2025-02-14 16:18:41 2024-10-30 18:43:20 2024-08-06 18:54:26 2024-05-02 19:27:57 2024-02-14 16:23:32 2023-10-31 16:21:57 2023-08-03 19:28:03 2023-04-27 20:38:17 2023-02-09 16:26:31 2022-11-03 19:24:04 2022-02-16 16:39:53 2021-02-08 19:24:56
fiscalYear 2025 2024 2023 2022 2021 2020
period FY Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 9 129M 9 445M 8 028M 11 973M 9 011M 9 301M 9 708M 10 944M 34 741M 34 248M 31 560M 7 629M 9 502M 7 989M 6 266M
shortTermInvestments 0 0 0 0 0 0 0 0 0 0 1 000 000 1 676M 1 976M 48M 4 381M
cashAndShortTermInvestments 9 129M 9 445M 8 028M 11 973M 9 011M 9 301M 9 708M 10 944M 34 741M 34 248M 31 561M 9 305M 11 478M 8 037M 10 647M
netReceivables 9 570M 8 490M 8 701M 7 501M 7 317M 6 934M 6 776M 7 942M 6 145M 5 830M 5 736M 6 392M 5 326M 5 839M 4 525M
accountsReceivables 9 570M 6 782M 7 268M 5 563M 4 895M 4 525M
otherReceivables 0 719M 674M 829M 944M 0
inventory 6 225M 6 346M 6 583M 6 998M 7 362M 7 995M 8 724M 9 518M 5 026M 4 978M 5 011M 4 930M 4 757M 4 086M 3 893M
prepaids 0 2 139M 1 647M 1 204M 1 223M 0
otherCurrentAssets 4 133M 3 604M 3 422M 419M 3 076M 2 976M 2 821M 281M 2 565M 2 324M 2 395M 355M 2 501M 200M 2 079M
totalCurrentAssets 29 057M 27 885M 26 734M 29 030M 26 766M 27 206M 28 029M 30 332M 48 477M 47 380M 44 703M 22 186M 24 062M 19 385M 21 144M
propertyPlantEquipmentNet 7 913M 7 220M 6 855M 6 543M 6 156M 6 097M 6 002M 5 941M 5 563M 5 532M 5 460M 5 427M 5 188M 5 184M 4 889M
goodwill 18 680M 18 676M 18 674M 18 637M 18 658M 18 616M 18 570M 18 629M 15 509M 15 531M 15 531M 15 529M 14 845M 14 890M 14 689M
intangibleAssets 22 276M 23 139M 24 614M 27 699M 28 920M 30 172M 31 372M 32 641M 13 150M 14 633M 15 393M 16 080M 13 266M 15 182M 16 587M
goodwillAndIntangibleAssets 40 956M 41 815M 43 288M 46 336M 47 578M 48 788M 49 942M 51 270M 28 659M 30 164M 30 924M 31 609M 28 111M 30 072M 31 276M
longTermInvestments 0 0 0 0 688M 1 162M 4 147M 0 1 222M 0 0 0 0 0 0
taxAssets 0 0 0 0 -688M 0 -49 942M 0 -1 222M 0 0 0 0 0 0
otherNonCurrentAssets 12 660M 13 221M 11 020M 9 930M 9 695M 7 654M 54 802M 9 611M 7 835M 7 193M 7 633M 5 899M 6 339M 6 524M 5 639M
totalNonCurrentAssets 61 529M 62 256M 61 163M 62 809M 64 117M 63 701M 64 951M 66 822M 42 057M 42 889M 44 017M 42 935M 39 638M 41 780M 41 804M
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 90 586M 90 141M 87 897M 91 839M 90 883M 90 907M 92 980M 97 154M 90 534M 90 269M 88 720M 65 121M 63 700M 61 165M 62 948M
totalPayables 20 890M 5 769M 4 459M 3 904M 3 150M 3 267M
accountPayables 20 890M 2 838M 3 010M 1 908M 2 147M 2 267M 1 628M 1 590M 1 358M 1 212M 1 320M 1 572M 1 204M 1 366M 1 421M
otherPayables 0 3 861M 2 869M 2 332M 1 784M 1 846M
accruedExpenses 0 12 451M 11 109M 9 093M 7 324M 6 723M
shortTermDebt 4 599M 2 153M 2 444M 3 550M 3 544M 5 528M 3 959M 1 443M 1 428M 2 167M 834M 1 591M 1 543M 87M 91M
capitalLeaseObligationsCurrent 0 0 0 0 0 0
taxPayables 0 0 0 0 0 0 0 1 664M 0 0 0 1 195M 0 701M 828M
deferredRevenue 0 0 0 0 0 -2 267M 0 0 0 0 0 0 0 0 0
otherCurrentLiabilities 0 16 800M 15 022M 1 329M 14 621M 13 722M 14 127M 1 381M 14 168M 13 718M 12 061M 1 099M 11 584M 1 623M 1 572M
totalCurrentLiabilities 25 489M 21 791M 20 476M 23 099M 20 312M 21 517M 19 714M 18 392M 16 954M 17 097M 14 215M 15 687M 14 331M 12 184M 11 653M
longTermDebt 50 005M 52 434M 53 760M 56 549M 56 854M 57 117M 60 061M 63 170M 59 040M 59 377M 60 761M 37 354M 37 161M 33 222M 32 895M
capitalLeaseObligationsNonCurrent 0 0 0 0 0 0
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 1 366M 1 458M 1 386M 1 616M 1 711M 1 780M 1 862M 2 354M 0 0 0 11M 0 0 0
otherNonCurrentLiabilities 5 068M 4 839M 4 847M 4 698M 4 479M 4 568M 6 321M 7 006M 6 884M 7 014M 8 396M 8 408M 42 969M 9 059M 8 991M
totalNonCurrentLiabilities 56 439M 58 731M 59 993M 62 863M 63 044M 63 465M 68 244M 72 530M 65 924M 66 391M 69 157M 45 773M 45 716M 42 281M 41 886M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilities 81 928M 80 522M 80 469M 85 962M 83 356M 84 982M 87 958M 90 922M 82 878M 83 488M 83 372M 61 460M 60 047M 54 465M 53 539M
treasuryStock 0 0 0 0 0 0
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 8 658M 33 841M 33 680M 33 533M 33 393M 33 204M 33 082M 33 070M 32 753M 32 601M 32 535M 32 514M 32 371M 32 096M 31 802M
retainedEarnings 0 -23 800M -25 708M -27 590M -25 530M -27 124M -27 870M -26 549M -24 971M -25 540M -26 919M -28 622M -28 066M -24 600M -21 408M
additionalPaidInCapital 0 0 0 0 0 0
accumulatedOtherComprehensiveIncomeLoss 0 -422M -544M -66M -336M -155M -190M -289M -126M -280M -268M -231M -652M -796M -985M
otherTotalStockholdersEquity 0 0 0 0 0 0
totalStockholdersEquity 8 658M 9 619M 7 428M 5 877M 7 527M 5 925M 5 022M 6 232M 7 656M 6 781M 5 348M 3 661M 3 653M 6 700M 9 409M
totalEquity 8 658M 9 619M 7 428M 5 877M 7 527M 5 925M 5 022M 6 232M 7 656M 6 781M 5 348M 3 661M 3 653M 6 700M 9 409M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 90 586M 90 141M 87 897M 91 839M 90 883M 90 907M 92 980M 97 154M 90 534M 90 269M 88 720M 65 121M 63 700M 61 165M 62 948M
totalInvestments 0 0 0 0 688M 1 162M 4 147M 0 1 222M 0 1 000 000 1 676M 1 976M 48M 4 381M
totalDebt 54 604M 54 587M 56 204M 60 099M 60 398M 62 645M 64 020M 64 613M 60 468M 61 544M 61 595M 38 945M 38 704M 33 309M 32 986M
netDebt 45 475M 45 142M 48 176M 48 126M 51 387M 53 344M 54 312M 53 669M 25 727M 27 296M 30 035M 31 316M 29 202M 25 320M 26 720M
fillingDate 2025-11-05 2025-08-06 2024-10-31 2024-08-07 2024-05-03 2023-10-31 2023-08-04 2023-04-28 2022-11-04
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
othertotalStockholdersEquity 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndStockholdersEquity 90 141M 87 897M 90 883M 90 907M 92 980M 90 534M 90 269M 88 720M 63 700M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2025 q4 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-12-31 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol AMGN AMGN AMGN AMGN AMGN AMGN AMGN AMGN AMGN AMGN AMGN AMGN AMGN AMGN AMGN
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 318 154 318 154 318 154 318 154 318 154 318 154 318 154 318 154 318 154 318 154 318 154 318 154 318 154 318 154 318 154
filingDate 2026-02-03 2025-02-14 2024-02-14 2023-02-09 2022-02-16 2021-02-09
acceptedDate 2026-02-03 16:03:07 2025-11-04 18:59:36 2025-08-05 19:13:42 2025-02-14 16:18:41 2024-10-30 18:43:20 2024-08-06 18:54:26 2024-05-02 19:27:57 2024-02-14 16:23:32 2023-10-31 16:21:57 2023-08-03 19:28:03 2023-04-27 20:38:17 2023-02-09 16:26:31 2022-11-03 19:24:04 2022-02-16 16:39:53 2021-02-08 19:24:56
fiscalYear 2025 2024 2023 2022 2021 2020
period FY Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome 7 711M 3 216M 1 432M 4 090M 2 830M 746M -113M 6 717M 1 730M 1 379M 2 841M 6 552M 2 143M 5 893M 7 264M
depreciationAndAmortization 0 1 307M 1 341M 5 592M 1 396M 1 400M 1 399M 4 071M 895M 896M 900M 3 417M 837M 3 398M 3 601M
deferredIncomeTax 0 -30M -422M -1 228M -110M -383M -401M -1 273M -447M -154M -49M -1 198M -333M -453M -287M
stockBasedCompensation 0 284M 157M 530M 136M 157M 103M 431M 0 689M 0 401M 0 341M 330M
changeInWorkingCapital 0 1 853M -759M 2 365M 570M 122M -692M -484M 53M 1 115M -754M -733M 310M -1 194M -216M
accountsReceivables 0 222M -515M 441M -342M -176M 486M -1 015M -342M -96M -144M -746M -62M -429M -427M
inventory 0 240M 239M 2 532M 681M 722M 806M 491M -54M 30M -58M -742M -241M -165M -215M
accountsPayables 0 -174M 589M 312M -122M 643M 23M -402M 156M -118M -253M 154M -44M -69M 45M
otherWorkingCapital 0 1 565M -1 072M -920M 353M -1 067M -2 007M 442M 293M 1 299M -299M 601M 657M -531M 381M
otherNonCashItems 2 247M -1 946M 531M 141M -1 251M 2 185M 1 979M -991M 678M 184M -1 874M 1 282M 21M 1 276M -195M
netCashProvidedByOperatingActivities 9 958M 4 684M 2 280M 11 490M 3 571M 2 459M 689M 8 471M 2 760M 4 109M 1 064M 9 721M 2 978M 9 261M 10 497M
investmentsInPropertyPlantAndEquipment -1 858M -436M -369M -1 096M -257M -238M -230M -1 112M -248M -271M -344M -936M -160M -880M -608M
acquisitionsNet 0 0 0 0 0 0 0 -26 989M 0 0 0 -3 727M 0 -2 686M -3 219M
purchasesOfInvestments 0 0 0 0 0 0 0 -1 000 000 -1 000 000 0 0 -2 587M -387M -8 900M -8 477M
salesMaturitiesOfInvestments 0 0 0 0 0 0 0 1 673M 0 1 000 000 1 674M 1 218M 400M 13 234M 6 978M
otherInvestingActivities -85M 50M 225M -12M -35M -75M
netCashProvidedByInvestingActivities -1 943M -1 046M -26 204M -6 044M 733M -5 401M
netDebtIssuance 0 -4 259M 25 676M 6 622M 795M 2 464M
longTermNetDebtIssuance 0 -4 259M 25 676M 6 622M 795M 2 464M
shortTermNetDebtIssuance 0 0 0 0 0 0
netStockIssuance 0 -200M 0 -6 360M -4 975M -3 486M
netCommonStockIssuance 0 -200M 0 -6 360M -4 975M -3 486M
commonStockIssuance 0 0 0 0 0 0
commonStockRepurchased 0 0 0 -200M 0 0 0 0 0 0 0 -6 360M 0 -4 975M -3 486M
netPreferredStockIssuance 0 0 0 0 0 0
netDividendsPaid 0 -4 832M -4 556M -4 196M -4 013M -3 755M
commonDividendsPaid 0 -4 832M -4 556M -4 196M -4 013M -3 755M
preferredDividendsPaid 0 0 0 0 0 0
otherFinancingActivities -10 859M -124M -72M -103M -78M -90M
netCashProvidedByFinancingActivities -10 859M -9 415M 21 048M -4 037M -8 271M -4 867M
effectOfForexChangesOnCash 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
netChangeInCash -2 844M 1 417M -782M 1 029M -290M -407M -1 236M 3 315M 493M 2 688M 23 931M -360M 4 299M 1 723M 229M
cashAtEndOfPeriod 9 129M 9 445M 8 028M 11 973M 9 011M 9 301M 9 708M 10 944M 34 741M 34 248M 31 560M 7 629M 9 502M 7 989M 6 266M
cashAtBeginningOfPeriod 11 973M 8 028M 8 810M 10 944M 9 301M 9 708M 10 944M 7 629M 34 248M 31 560M 7 629M 7 989M 5 203M 6 266M 6 037M
operatingCashFlow 9 958M 4 684M 2 280M 11 490M 3 571M 2 459M 689M 8 471M 2 760M 4 109M 1 064M 9 721M 2 978M 9 261M 10 497M
capitalExpenditure -1 858M -436M -369M -1 096M -257M -238M -230M -1 112M -248M -271M -344M -936M -160M -880M -608M
freeCashFlow 8 100M 4 248M 1 911M 10 394M 3 314M 2 221M 459M 7 359M 2 512M 3 838M 720M 8 785M 2 818M 8 381M 9 889M
incomeTaxesPaid 0 0 0 0 0 0
interestPaid 0 0 0 0 0 0
fillingDate 2025-11-05 2025-08-06 2024-10-31 2024-08-07 2024-05-03 2023-10-31 2023-08-04 2023-04-28 2022-11-04
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
otherInvestingActivites 22M -20M 47M 21M 13M -13M 59M 28M -120M
netCashUsedForInvestingActivites -414M -389M -210M -217M -217M -262M -211M 1 358M -267M
debtRepayment 0 -1 301M -2 200M -1 400M -410M -750M 0 -704M 0
commonStockIssued 0 0 0 0 0 0 0 0 0
dividendsPaid -1 282M -1 280M -1 210M -1 209M -1 208M -1 140M -1 139M -1 137M -1 038M
otherFinancingActivites -1 571M -92M -241M -40M -90M -115M -71M 23 350M 2 626M
netCashUsedProvidedByFinancingActivities -2 853M -2 673M -3 651M -2 649M -1 708M -2 005M -1 210M 21 509M 1 588M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Earning call transcript

2025 q4
2026-02-03 ET (fiscal 2025 q4)
2025 q3
2025-11-04 ET (fiscal 2025 q3)
2025 q2
2025-08-05 ET (fiscal 2025 q2)
2025 q1
2025-05-01 ET (fiscal 2025 q1)
2024 q4
2025-02-04 ET (fiscal 2024 q4)
2024 q3
2024-10-30 ET (fiscal 2024 q3)
2024 q2
2024-08-06 ET (fiscal 2024 q2)
2024 q1
2024-05-02 ET (fiscal 2024 q1)
2023 q4
2024-02-06 ET (fiscal 2023 q4)
2023 q3
2023-10-31 ET (fiscal 2023 q3)
2023 q2
2023-08-03 ET (fiscal 2023 q2)
2023 q1
2023-04-27 ET (fiscal 2023 q1)
2022 q4
2023-01-31 ET (fiscal 2022 q4)
2022 q3
2022-11-03 ET (fiscal 2022 q3)
2022 q2
2022-08-04 ET (fiscal 2022 q2)
2022 q1
2022-04-27 ET (fiscal 2022 q1)

SEC forms

Show financial reports only

SEC form 8
2026-02-03 16:03 ET
Amgen reported for 2025 q4
SEC form 8
2026-02-03 16:03 ET
Amgen published news for 2025 q4
SEC form 8
2026-01-30 08:00 ET
Amgen published news for 2025 q4
SEC form 8
2026-01-30 08:00 ET
Amgen published news for 2025 q4
SEC form 10
2025-11-04 23:59 ET
Amgen reported for 2025 q3
SEC form 8
2025-11-04 16:04 ET
Amgen published news for 2025 q3
SEC form 8
2025-11-04 16:04 ET
Amgen reported for 2025 q3
SEC form 10
2025-08-05 23:13 ET
Amgen reported for 2025 q2
SEC form 8
2025-08-05 20:03 ET
Amgen published news for 2025 q2
SEC form 8
2025-08-05 20:03 ET
Amgen reported for 2025 q2
SEC form 10
2025-05-02 00:00 ET
Amgen reported for 2025 q1
SEC form 10
2025-05-01 22:54 ET
Amgen reported for 2025 q1
SEC form 8
2025-05-01 20:04 ET
Amgen reported for 2025 q1
SEC form 8
2025-05-01 20:04 ET
Amgen published news for 2025 q1
SEC form 10
2025-02-14 21:18 ET
Amgen published news for 2024 q4
SEC form 10
2025-02-14 00:00 ET
Amgen published news for 2024 q4
SEC form 8
2025-02-04 16:05 ET
Amgen published news for 2024 q4
SEC form 8
2025-02-04 16:05 ET
Amgen reported for 2024 q4
SEC form 10
2024-10-31 00:00 ET
Amgen reported for 2024 q3
SEC form 10
2024-10-30 18:43 ET
Amgen reported for 2024 q3
SEC form 8
2024-10-30 16:06 ET
Amgen published news for 2024 q3
SEC form 8
2024-10-30 16:06 ET
Amgen reported for 2024 q3
SEC form 10
2024-08-07 00:00 ET
Amgen reported for 2024 q2
SEC form 10
2024-08-06 18:54 ET
Amgen reported for 2024 q2
SEC form 8
2024-08-06 16:05 ET
Amgen reported for 2024 q2
SEC form 8
2024-08-06 16:05 ET
Amgen published news for 2024 q2
SEC form 10
2024-05-03 00:00 ET
Amgen published news for 2024 q1
SEC form 10
2024-05-02 19:27 ET
Amgen published news for 2024 q1
SEC form 8
2024-05-02 16:03 ET
Amgen reported for 2024 q1
SEC form 8
2024-05-02 16:03 ET
Amgen published news for 2024 q1
SEC form 10
2024-02-14 00:00 ET
Amgen published news for 2023 q4
SEC form 10
2023-10-31 16:21 ET
Amgen reported for 2023 q3
SEC form 8
2023-10-31 07:15 ET
Amgen reported for 2023 q3
SEC form 10
2023-10-31 00:00 ET
Amgen published news for 2023 q3
SEC form 10
2023-08-04 00:00 ET
Amgen published news for 2023 q2
SEC form 10
2023-08-03 19:28 ET
Amgen published news for 2023 q2
SEC form 6
2023-08-03 17:48 ET
Amgen published news for 2023 q2
SEC form 6
2023-08-03 16:12 ET
Amgen reported for 2023 q2
SEC form 8
2023-08-03 00:00 ET
Amgen published news for 2023 q2
SEC form 6
2023-06-14 19:31 ET
Amgen published news for 2023 q1
SEC form 6
2023-06-14 19:21 ET
Amgen published news for 2023 q1
SEC form 6
2023-06-05 08:00 ET
Amgen published news for 2023 q1
SEC form 10
2023-04-28 00:00 ET
Amgen published news for 2023 q1
SEC form 8
2023-04-27 00:00 ET
Amgen published news for 2023 q1
SEC form 10
2023-02-09 00:00 ET
Amgen reported for 2022 q4
SEC form 10
2022-11-04 00:00 ET
Amgen reported for 2022 q3
SEC form 8
2022-11-03 00:00 ET
Amgen reported for 2022 q3
SEC form 10
2022-08-05 00:00 ET
Amgen reported for 2022 q2
SEC form 8
2022-08-04 00:00 ET
Amgen reported for 2022 q2
SEC form 10
2022-04-28 00:00 ET
Amgen reported for 2022 q1
SEC form 8
2022-04-27 00:00 ET
Amgen reported for 2022 q1
SEC form 10
2022-02-16 00:00 ET
Amgen published news for 2021 q4
SEC form 8
2022-02-07 00:00 ET
Amgen published news for 2021 q4
SEC form 10
2021-11-03 00:00 ET
Amgen published news for 2021 q3
SEC form 8
2021-11-02 00:00 ET
Amgen published news for 2021 q3
SEC form 10
2021-08-04 00:00 ET
Amgen published news for 2021 q2
SEC form 8
2021-08-03 00:00 ET
Amgen published news for 2021 q2
SEC form 10
2021-04-28 00:00 ET
Amgen published news for 2021 q1
SEC form 8
2021-04-27 00:00 ET
Amgen published news for 2021 q1